But pharmaceutical companies are beginning to realize that the populations of those nations also represent potential untapped markets because many of their health issues have not previously been the inspiration for pharmaceutical research.
The author also acknowledges that some drug companies have experimented with differential pricing to allow them to market products to less wealthy populations. There are concerns within the industry that lower-price products introduced into specific markets could be diverted back to their wealthier markets. However, there are various measures that can be taken to mitigate that risk, such as different colored pills and strict penalties against distributors caught misdirecting products from...
The author avoids providing any firm conclusion except to suggest that the pharmaceutical industry may very well be undergoing considerable change for the reasons elucidated.
Evidence, Credibility, and Believability
The author presents information from a wide variety of credible industry experts and insiders. Those sources include principals at major pharmaceutical companies, acknowledged industry experts, and outside financial analysts employed by major independent organizations reporting on the pharmaceutical industry. Ultimately, the article comes across as objective, well-researched, and reliable in its information and in the implications for the future articulated by the author.
